The goal for many treating lower-risk myelodysplastic syndrome (MDS), is to reduce transfusion dependence after the loss of response to erythropoietic growth factors (ESAs). Valeria Santini, MD, University of Florence, Florence, Italy, talks on current progress in the treatment of lower-risk myelodysplastic syndromes (MDS), highlighting the use of luspatercept, a recombinant fusion protein that limits SMAD2 and SMAD3 signaling and various drugs currently under evaluation such as imetelstat, a telomerase inhibitor, and roxadustat, a HIF prolyl-hydroxylase inhibitor. This interview took place during the 2021 European School of Hematology (ESH) 7th Translational Research E-Conference on Myelodysplastic Syndromes.
